Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intrinsic Value
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one ITCI stock under the Base Case scenario is 46.77 USD. Compared to the current market price of 72.37 USD, Intra-Cellular Therapies Inc is Overvalued by 35%.
Valuation Backtest
Intra-Cellular Therapies Inc
Run backtest to discover the historical profit from buying and selling ITCI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Intra-Cellular Therapies Inc
| Current Assets | 667.8m |
| Cash & Short-Term Investments | 497.9m |
| Receivables | 114m |
| Other Current Assets | 55.8m |
| Non-Current Assets | 60.5m |
| PP&E | 14.6m |
| Other Non-Current Assets | 45.9m |
| Current Liabilities | 123.5m |
| Accounts Payable | 11.5m |
| Accrued Liabilities | 112.1m |
| Non-Current Liabilities | 13.3m |
| Other Non-Current Liabilities | 13.3m |
Earnings Waterfall
Intra-Cellular Therapies Inc
|
Revenue
|
464.4m
USD
|
|
Cost of Revenue
|
-33.7m
USD
|
|
Gross Profit
|
430.6m
USD
|
|
Operating Expenses
|
-590m
USD
|
|
Operating Income
|
-159.4m
USD
|
|
Other Expenses
|
19.7m
USD
|
|
Net Income
|
-139.7m
USD
|
Free Cash Flow Analysis
Intra-Cellular Therapies Inc
What is Free Cash Flow?
ITCI Profitability Score
Profitability Due Diligence
Intra-Cellular Therapies Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Intra-Cellular Therapies Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ITCI Solvency Score
Solvency Due Diligence
Intra-Cellular Therapies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Intra-Cellular Therapies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ITCI Price Targets Summary
Intra-Cellular Therapies Inc
According to Wall Street analysts, the average 1-year price target for ITCI is 91.5 USD with a low forecast of 65.65 USD and a high forecast of 126 USD.
Ownership
ITCI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ITCI Price
Intra-Cellular Therapies Inc
| Average Annual Return | 55.09% |
| Standard Deviation of Annual Returns | 77.42% |
| Max Drawdown | -49% |
| Market Capitalization | 7B USD |
| Shares Outstanding | 96 807 200 |
| Percentage of Shares Shorted | 4.15% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 512 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The firm provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The firm's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one ITCI stock under the Base Case scenario is 46.77 USD.
Compared to the current market price of 72.37 USD, Intra-Cellular Therapies Inc is Overvalued by 35%.
You don't have any saved screeners yet
